AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative Colitis | MicrobiomeTrials← Back to trialsNCT07619638
AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative Colitis
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2026-10-10Est. Completion: 2027-12-30
Enrollment target: 162 participants Locations- Ege University, Izmir, Turkey (Türkiye)
Other microbiome trials you might be interested in
Recurrent C. Difficile (rCDI)Ulcerative Colitis (UC)Metabolic Syndrome (MetS)
The gut microbiota plays a key role in immunity and metabolism and contributes to diseases such as recurrent C. difficil…
Rome, ItalyEst. completion Jan 19, 2029
Crohn's DiseaseUlcerative Colitis (UC)Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)
Through a pilot randomized controlled trial (RCT), we aim to test the feasibility and preliminary impact of two online p…
Los Angeles, United StatesEst. completion Jul 2027
Ulcerative Colitis (Disorder)
This multicenter longitudinal observational cohort study aims to characterize objective disease-control trajectories, tr…
Multiple LocationsEst. completion Dec 30, 2031